LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

Revvity Inc

Slēgts

SektorsVeselības aprūpe

99.97 2.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

99.51

Max

100.54

Galvenie mērījumi

By Trading Economics

Ienākumi

-58M

41M

Pārdošana

-61M

711M

P/E

Sektora vidējais

48.341

49.712

EPS

1.06

Dividenžu ienesīgums

0.28

Peļņas marža

5.726

Darbinieki

11,000

EBITDA

-38M

180M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+3.75% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.28%

2.36%

Nākamie ieņēmumi

2026. g. 27. jūl.

Nākamais dividenžu datums

2026. g. 7. aug.

Nākamais Ex dividenžu datums

2026. g. 17. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.5B

11B

Iepriekšējā atvēršanas cena

97.58

Iepriekšējā slēgšanas cena

99.97

Ziņu noskaņojums

By Acuity

36%

64%

82 / 342 Rangs Healthcare

Revvity Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Par Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat